Following a consistent trend of annual or semi-annual expansion, Pfizer will increase its sales force during the fourth quarter of the year.
Following a consistent trend of annual or semi-annual expansion, Pfizer will increase its sales force during the fourth quarter of the year.
In early 1998, the number of Pfizer reps grew to approximately 3,800, but the success of new product launches and anticipation about upcoming launches has Pfizer preparing to reinforce its troops. Industry sources say the number of anticipated new hires hovers just above 600 reps and an additional 75 managers.
Recent hires will staff a new primary care field force, according to Hank McCrorie, group vice president of sales for Pfizer. A new specialty field force is also part of Pfizer's plans for the future.
"We continue to expand because we continue to introduce new products and we continue to join in copromotions," McCrorie said. "We need additional personnel to support in-line products as well as products we intend to launch in 1999."
Obviously, Pfizer's launch of Viagra for erectile dysfunction created a flurry of activity in the field for its reps. According to Scott-Levin, Newton, PA, Viagra generated more than 592,000 prescriptions in its first month on the market and gained nearly 95% of new prescriptions in the erectile dysfunction market. As of mid-May, 1.4 million prescriptions for the product had been dispensed.
McCrorie is stoical about the positive fallout Viagra's success had on Pfizer's reps and their ability to detail other unrelated products, such as Trovan, Zyrtec, Zithromax and Zoloft.
"Anytime you introduce new exciting products, doctors want to see you, and when they want to see you, that gives you greater access," he said. "But that's not just Viagra. That's true anytime you have innovative new products."
Pfizer is hoping that will be the case when it begins copromoting Celexa, a COX-2 inhibitor anti-inflammatory drug, with Searle, after the product's anticipated market approval from the Food and Drug Administration. The copromotion, given Pfizer's recent expansion and the pending merger of Monsanto (Searle's parent company) and American Home Products, will have more than 8,500 sales reps available for details. PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.